WEKO3
アイテム
Phase II Study of 4-fraction Carbon Ion Radiotherapy for Hepatocellular Carcinoma
https://repo.qst.go.jp/records/69127
https://repo.qst.go.jp/records/6912703f54c4e-e200-41e9-add1-7adfddadbde9
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2007-10-12 | |||||
| タイトル | ||||||
| タイトル | Phase II Study of 4-fraction Carbon Ion Radiotherapy for Hepatocellular Carcinoma | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Katou, Hirotoshi
× Katou, Hirotoshi× Yamada, Shigeru× Yasuda, Shigeo× Maeda, Yukiteru× Kamada, Tadashi× Mizoe, Junetsu× Ootou, Masao× Tsujii, Hirohiko× 加藤 博敏× 山田 滋× 安田 茂雄× 前田 幸輝× 鎌田 正× 溝江 純悦× 大藤 正雄× 辻井 博彦 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Introduction: A phase II study of Carbon Ion Radiotherapy (CIRT) for HCC according to a 52.8 cobalt gray equivalent (GyE) /4-fraction/1-week regime was conducted from April 2001 to February 2003. Purpose: To evaluate the efficacy of 4-fraction CIRT for HCC. Methods: Eligibility criteria were as follows: biopsy-proven, recurrent or residual tumor after other treatments or no indication for any other treatment; no prior radiotherapy for target tumors; Child-Pugh grade A or B. Results: Forty-seven patients with chronic liver disease of Child-Pugh grade A in 37, B in 10 were enrolled. The median age at therapy was 69 years. The median tumor size was 3.7 (1.2-7.5)cm in diameter. During a median follow-up of 60 (48-70)months, no treatment-related hepatic failure and death occurred. Incidence of grade 3 early hepatic toxicity in the serum-GPT, ALB, T.BIL, PT and ALP according to NCI-CTC (ver.2) was 0, 11, 0, 2, and 13%, respectively. No other grade 3 or worse adverse effect occurred. In 92% of patients, the Child-Pugh score did not increase by more than 1 point within 1 year after the therapy. Local control rate was 96% at 1 to 5 years. Overall and cause-specific survival rates at 3 and 5 years were 57% and 67%, 34% and 42%, respectively. Those in the 27 patients initially treated with CIRT were 63% and 81%, 40% and 52%, respectively. Conclusion: Four-fraction CIRT for HCC seems to have a promising potential as a new, radical, and minimally invasive therapeutic option for HCC. | |||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | ILCA's First Annual Conference | |||||
| 発表年月日 | ||||||
| 日付 | 2007-10-07 | |||||
| 日付タイプ | Issued | |||||
